Zeneca has taken its COVID-19 vaccine trial after a break for the security check

This story has been updated to reflect AstraZeneca’s investigational vaccine shot. AstraZeneca, the British pharmaceutical company behind one of the most promising candidates COVID-19 vaccine in the world, took his studies in the United Kingdom after that due to break “a single case of unexplained illness,” he announced company on September 12, while the first Zeneca not specify the nature of the study participants “unexplained illness,” an unnamed source told the New York Times that a study participant in the UK was recently diagnosed with inflammatory disease of the spinal cord is affected. After a security check, AstraZeneca, which has helped to develop its vaccine candidates with Oxford University, said an independent team of researchers concluded that the British study to continue safely. It is not uncommon for drugs tests or vaccines to hit malice, even at an advanced stage. To go through several stages of the reason for test vaccines, with increasing number of patients is still rare but potentially serious side effects. “Clinical trials often receive break,” says Dr. Paul Duprex, director of the University of Pittsburgh Center for Vaccine Research. “A break in a clinical trial is a voluntary action and shows that the process works in practice. It is not the car’s brakes at full speed, we definitely get this across the finish line.” A review does not necessarily mean a candidate vaccine it is not yet certain that the process of being resolved. “Pause does not mean stop,” says Duprex. “It means that we took our foot off the accelerator to do due diligence.” Zeneca decision may pause its study actually inspire confidence in the scientific process. Some medical experts and members of the public expressed concern that political pressure can pharmaceutical companies ready to run a 19-COVID vaccine before it has certainly proven effective. The US president Donald Trump has repeatedly said he wants a vaccine approved by election day in November, for example. Pharmaceutical companies have pushed back. In a promise of this month, the CEOs of nine pharmaceutical companies, including AstraZeneca, promised to “science is” and reiterated their “unwavering commitment to the development and testing potential vaccines for COVID-19 in respect of high ethical standards and scientific principles highly publicized break. “the decision of its Zeneca (and potentially profitable) a study shows that commitment. Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases and the top-19 COVID experts in the country, the decision as a “safety valve”, although one “unlucky.” Duprex adds that pharmaceutical companies know their facts crown studies under a global microscope and are therefore likely work with a huge amount of caution. “This is just part of the normal process,” he says. If we were not in a pandemic, “we would not be on the phone talking about it.” Image copyright
Jakub Porzycki / NurPhoto-Getty Images